SCHEMBL1400933

SCHEMBL1400933

CN(C(=O)O)c1cccc(Br)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 2/20 0.48
MTNR1B P49286 2/20 0.48
ALDH1A1 P00352 4/20 0.43
LMNA P02545 2/20 0.43
KDM4E B2RXH2 1/20 0.43
PARP1 P09874 1/20 0.41
MAPT P10636 2/20 0.41
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
POLB P06746 1/20 0.41
ALPG P10696 1/20 0.41
ATM Q13315 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
TLR9 Q9NR96 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
SIGMAR1 Q99720 2/20 0.40
RXRA P19793 1/20 0.40
RXRB P28702 1/20 0.40
RXRG P48443 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2378380 0.85 MTNR1A (0.48) MTNR1AMTNR1BALDH1A1LMNAKDM4E
SCHEMBL10947337 0.83 MTNR1A (0.43) MTNR1AMTNR1BALDH1A1LMNAKDM4E
SCHEMBL11541741 0.83 MTNR1A (0.43) MTNR1AMTNR1BALDH1A1LMNAKDM4E
SCHEMBL27526910 0.82 KMT2A (0.54) MTNR1AMTNR1BKDM4EKMT2AATM
SCHEMBL10947342 0.81 FAAH (0.41) MTNR1AMTNR1BALDH1A1LMNAKDM4E
SCHEMBL31222334 0.80 RIPK1 (0.46) MTNR1AMTNR1BALDH1A1LMNAKDM4E
SCHEMBL11340728 0.80 MTNR1A (0.44) MTNR1AMTNR1BALDH1A1LMNAKDM4E
SCHEMBL19259811 0.79 ALDH1A1 (0.33) MTNR1AMTNR1BALDH1A1LMNAKDM4E
SCHEMBL515035 0.79 MTNR1A (0.40) MTNR1AMTNR1BALDH1A1LMNAKDM4E
SCHEMBL7983296 0.79 RIPK1 (0.41) MTNR1AMTNR1BALDH1A1LMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357208-A1 MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS Epizyme, Inc. (US) 2023-11-09 US disclosed
WO-2023132353-A1 METHOD FOR REMOVING TERT-BUTOXYCARBONYL GROUPS 中外製薬株式会社 2023-07-13 WO disclosed
US-11685732-B2 MYST family histone acetyltransferase inhibitors Epizyme, Inc. (US) 2023-06-27 US disclosed
US-20220162197-A1 MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS Epizyme, Inc. 2022-05-26 US disclosed
EP-3716964-A1 MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS Epizyme, Inc. (US) 2020-10-07 EP disclosed
CN-101679225-B Method for the synthesis of (z)-3-[2-butoxy-3'-(3-heptyl-1-methyl-ureido)-biphenyl-4-yl]-2-methoxy-acrylic acid GALDERMA RES & DEV 2014-04-02 CN disclosed
US-20130303549-A1 NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPARY TYPE RECEPTORS AND COSMETIC/PHARMACEUTICAL COMPOSITIONS COMPRISED THEREOF GALDERMA RES & DEV (FR) 2013-11-14 US disclosed
US-8513297-B2 Biaromatic compounds that modulate PPARy type receptors and cosmetic/pharmaceutical compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2013-08-20 US disclosed
US-8383652-B2 Biaromatic compounds that modulate PPAR-receptors GALDERMA RESEARCH & DEVELOPMENT (FR) 2013-02-26 US disclosed
US-8357819-B2 Method for the synthesis of (Z)-3-[2-butoxy-3′-(3-heptyl-1-methyl-ureido)-biphenyl-4-yl]-2-methoxy-acrylic acid GALDERMA RESEARCH & DEVELOPMENT (FR) 2013-01-22 US disclosed
EP-1638964-A1 NOVEL COMPOUNDS THAT MODULATE PPAR-GAMMA TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS Galderma Research & Development, S.N.C. (FR) 2006-03-29 EP disclosed
WO-2006018326-A1 NOVEL BIAROMATIC COMPOUNDS THAT ACTIVATE PPAR TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2006-02-23 WO disclosed
US-20050256116-A1 Novel biaromatic compounds which activate PPARy type receptors and cosmetic/pharmaceutical compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-11-17 US disclosed
WO-2005108352-A1 NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE PPARϜ-TYPE RECEPTORS, THEIR PROCESS OF PREPARATION AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-11-17 WO disclosed
US-20050137238-A1 Biaromatic ligand activators of PPARgamma receptors GALDERMA RESEARCH & DEVELOPMENT S.N.C. 2005-06-23 US disclosed
US-6908939-B2 Biaromatic ligand activators of PPARγ receptors GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2005-06-21 US disclosed
WO-2004113331-A1 NOVEL COMPOUNDS THAT MODULATE PPARϜ TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2004-12-29 WO disclosed
EP-1458697-A1 BIPHENYLMETHYL-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE AS PPAR-GAMMA ACTIVATORS Galderma Research & Development, S.N.C. (FR) 2004-09-22 EP disclosed
US-20030134885-A1 Biaromatic ligand activators of PPARgamma receptors GALDERMA RESEARCH & DEVELOPMENT (FR) 2003-07-17 US disclosed
WO-2003055867-A1 BIPHENYLMETHYL-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE AS PPAR-GAMMA ACTIVATORS GALDERMA RESEARCH & DEVELOPMENT, SNC (FR) 2003-07-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220162197-A1 MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS EP300, KAT2A, KAT6A MTNR1A 3379/4885MTNR1B 3936/4885ALDH1A1 2786/4885
US-20230357208-A1 MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS EP300, KAT2A, KAT6A MTNR1A 3379/4885MTNR1B 3936/4885ALDH1A1 2786/4885
US-11685732-B2 MYST family histone acetyltransferase inhibitors EP300, KAT2A, KAT6A MTNR1A 3379/4885MTNR1B 3936/4885ALDH1A1 2786/4885
US-20130303549-A1 NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPARY TYPE RECEPTORS AND COSMETIC/PHARMACEUTICAL COMPOSITIONS COMPRISED THEREOF PPARG, PPARD, PPARA MTNR1A 130/4885MTNR1B 230/4885ALDH1A1 486/4885
US-20050256116-A1 Novel biaromatic compounds which activate PPARy type receptors and cosmetic/pharmaceutical compositions comprised thereof PPARG, PPARA, PPARD MTNR1A 234/4885MTNR1B 400/4885ALDH1A1 531/4885
US-20050137238-A1 Biaromatic ligand activators of PPARgamma receptors PPARG, PPARA, PPARD MTNR1A 52/4885MTNR1B 240/4885ALDH1A1 283/4885
US-20030134885-A1 Biaromatic ligand activators of PPARgamma receptors PPARG, PPARA, PPARD MTNR1A 45/4885MTNR1B 215/4885ALDH1A1 257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.